Internal Medicine, Pulmonary Disease · San Juan, PR
NPI
1295066124
Since 2010
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
Ave Arterial Hostos # 239, Capital Center Bldg. Suite 606
San Juan, PR, 00918
Phone (787) 250-1193
Groups this clinician bills Medicare through
Medicare paid, 2024
$16K
315 services
Medicare patients, 2024
31
Average age 79
Drug cost, 2024
$1.7M
10,286 prescriptions
Company payments, 2025
$305
From 2 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Carlos R Alcala Marquez was code 94200 (pulmonary function testing), 48 times for 22 patients. In total Carlos R Alcala Marquez billed 315 services in 11 codes, and Medicare paid $16K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-05-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 94200 Pulmonary Function Testing | Office | 48 | 22 | $10.79 | $518 |
| 94375 Pulmonary Function Testing | Office | 48 | 22 | $27.26 | $1,309 |
| 99213 Office E&M - Established | Office | 43 | 18 | $62.44 | $2,685 |
| 94664 E&M - Miscellaneous | Office | 38 | 17 | $12.64 | $480 |
| 94640 Treatment - Miscellaneous | Office | 31 | 15 | $5.47 | $170 |
By year: 2022 $30K for 360 services; 2023 $33K for 431 services; 2024 $16K for 315 services.
Medicare prescription drug claims, 2024
In 2024, the drug Carlos R Alcala Marquez prescribed most often to Medicare patients was Montelukast Sodium, with 2,012 prescriptions and refills. In total Carlos R Alcala Marquez wrote 10,286 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Montelukast Sodium Generic | 2,012 | 2,505 | 407 | $19K |
| Breo Ellipta Fluticasone/Vilanterol | 1,218 | 1,246 | 237 | $506K |
| Fluticasone Propionate Generic | 1,130 | 1,231 | 241 | $19K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 1,117 | 1,129 | 362 | $48K |
| Wixela Inhub Fluticasone Propion/Salmeterol | 992 | 1,020 | 206 | $154K |
| Desloratadine Generic | 596 | 602 | 136 | $12K |
| Famotidine Generic | 501 | 570 | 132 | $3,372 |
| Spiriva Respimat Tiotropium Bromide | 417 | 421 | 81 | $222K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 308 | 316 | 50 | $209K |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 255 | 268 | 54 | $62K |
| Levocetirizine Dihydrochloride Generic | 240 | 248 | 48 | $3,030 |
| Methylprednisolone Generic | 238 | 241 | 184 | $2,273 |
| Arnuity Ellipta Fluticasone Furoate | 208 | 210 | 34 | $50K |
| Atrovent Hfa Ipratropium Bromide | 165 | 165 | 63 | $79K |
| Omeprazole Generic | 124 | 138 | 32 | $765 |
Brand drugs: - claims; generic drugs: 6,401 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Carlos R Alcala Marquez $305 ($305 in general payments such as food, travel and fees) from 2 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $274.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.